Fri, May 9, 9:20 PM (13 days ago)
**Vivos Inc. (RDGL) Q1 2025 Financial Performance Summary** Vivos Inc. (RDGL) reported a challenging first quarter of 2025, with significant losses and operational uncertainties. Here are the key points: **Financial Health:** - **Revenue:** $26,748 (up from $4,500 in Q1 2024). - **Net Loss:** $834,696 (up from $558,539 in Q1 2024). - **Operating Expenses:** $854,449 (up from $575,629 in Q1 2024). - **Cash Position:** $3,265,100 (up from $2,212,548 in Q4 2024). **Profit Margins:** - Gross margin was negative, indicating higher costs of goods sold than revenue. - Operating margin was also negative, reflecting high operating expenses. **Cash Flow:** - Net cash used in operating activities was $455,198 (up from $351,458 in Q1 2024). - Net cash provided by financing activities was $1,507,750 (up from $130,000 in Q1 2024). **Earnings Changes:** - The net loss per share was $0.00, consistent with Q1 2024. **Quarterly Performance Discussion:** - Revenue growth was driven by increased IsoPet® treatments and certification services. - Operating expenses increased due to higher professional fees, research and development, and general administrative expenses. - The company raised $1,506,250 through the issuance of common stock and warrants. **Trends and Uncertainties:** - Vivos Inc. continues to face significant financial challenges, with recurring losses and high cash burn rates. - The company is dependent on raising additional capital to fund its operations and development efforts. - Uncertainties include regulatory approvals, market acceptance, and competitive pressures. **Future Operations Impact:** - The company plans to use proceeds from its Regulation A+ Offering to expand its animal therapy market, enhance its quality management system, and fund human clinical studies. - Vivos Inc. aims to secure additional funding to support its long-term goals, including regulatory approvals and commercialization of its brachytherapy products. **Conclusion:** Vivos Inc. is in a critical phase, requiring substantial additional funding to continue its operations and development efforts. The company's future depends on securing regulatory approvals, expanding its market presence, and successfully commercializing its products.